Valuation: Omeros Corporation

Market Cap 816M 717M 670M 615M 1.15B 78.2B 1.18B 7.94B 3.11B 38.7B 3.07B 3B 134B P/E 2026 *
-195x
P/E 2027 * 152x
Enterprise Value 816M 717M 670M 615M 1.15B 78.2B 1.18B 7.94B 3.11B 38.7B 3.07B 3B 134B EV / Sales 2026 *
12x
EV / Sales 2027 * 5.71x
Free-Float
96.44%
Yield 2026 *
-
Yield 2027 * -
1 day+3.46%
1 week+22.46%
Current month+22.71%
1 month+34.60%
3 months-20.45%
6 months-1.19%
Current year-32.05%
1 week 9.6
Extreme 9.6
11.89
1 month 9
Extreme 9
11.89
Current year 6.7
Extreme 6.7023
17.63
1 year 3.44
Extreme 3.435
17.65
3 years 0.92
Extreme 0.92
17.65
5 years 0.92
Extreme 0.92
17.65
10 years 0.92
Extreme 0.92
27.09
Manager TitleAgeSince
Chief Executive Officer 67 16/06/1994
Director of Finance/CFO 62 30/06/2024
Chief Tech/Sci/R&D Officer 70 01/11/2019
Director TitleAgeSince
Chairman 67 16/06/1994
Director/Board Member 86 01/01/1995
Director/Board Member 72 01/01/1995
Date Insider Type Main position Quantity % Market Cap.
22/07/26 Free

General Counsel

105,000 0.1451%
22/07/26 Free

Chief Financial Officer

105,000 0.1451%
22/07/26 Free

Chief Executive Officer

1,000,000 1.3817%
Change 5-day change 1-year change 3-year change Capi.($)
+3.46%+22.46%+181.20%+167.66% 816M
+0.47%+2.03%+51.54%+70.84% 55.01B
+2.83%+0.04%+38.07%+82.59% 54.24B
+0.54%+0.67%-17.59%-13.47% 23.38B
-0.97%-5.06%+1.35%+383.00% 22.57B
+2.07%+1.44%+23.06%-9.05% 20.19B
-2.15%+0.78%+24.67%-31.03% 17.86B
-2.14%-2.72%+30.26%+536.72% 15.5B
-3.14%-8.09%+160.68%+292.18% 14.2B
-2.09%-1.41%+24.65%+178.74% 14.2B
Average -0.08%+0.54%+51.79%+165.82% 23.8B
Weighted average by Cap. +0.31%-0.69%+36.45%+130.74%

Financials

2026 *2027 *
Net sales 67.83M 59.61M 55.64M 51.06M 95.58M 6.5B 97.94M 660M 258M 3.22B 255M 249M 11.11B 143M 126M 117M 108M 202M 13.71B 207M 1.39B 544M 6.78B 537M 526M 23.45B
Net income -12.1M -10.63M -9.92M -9.11M -17.05M -1.16B -17.47M -118M -46.02M -574M -45.43M -44.44M -1.98B 1.25M 1.1M 1.03M 941K 1.76M 120M 1.8M 12.16M 4.75M 59.25M 4.69M 4.59M 205M
Net Debt - -
Logo Omeros Corporation
Omeros Corporation is a clinical-stage biopharmaceutical company. The Company focuses on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan indications, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. Its commercial product, YARTEMLEA, is the approved inhibitor of the lectin pathway of complement. YARTEMLEA is used for the treatment of TA-TMA in adults and in children ages two years and older. YARTEMLEA selectively inhibits MASP-2, blocking pathway activation while preserving classical and alternative complement pathway functions.
Employees
175
Date Price Change Volume
30/07/26 $11.67 +3.46% 1,684,938
28/07/26 $11.28 -0.53% 2,222,452
27/07/26 $11.34 +15.83% 3,360,609
24/07/26 $9.790 -4.77% 799,038
23/07/26 $10.28 +4.47% 1,544,963
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
11.28USD
Average target price
33.00USD
Spread / Average Target
+192.55%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OMER Stock